AVBPArriVent BioPharma, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+19% of shares).
Rangebound, no clear trend. Oversold (RSI 20). Price is −37% vs its 200-day average.
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How AVBP is trading
ArriVent BioPharma, Inc. is −5.3% over the past year while the S&P 500 is +18%: 24 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −37%
vs 200-day average · a clear downtrend
- RSI (14)
- 20
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 51%
Below its 52-week high
Details›
- Last close2026-10-09
- $16.72
- 1 monthS&P 500 +2.7%
- −42%
- 1 yearS&P 500 +18%
- −5.3%
- vs 50-day average$28.73
- −42%
- 52-week high
- $33.83
- 52-week low
- $15.12
- Annualised volatility
- 65%
| Year | Return |
|---|---|
| 2026 (year to date) | −17% |
| 2025 | −24% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 2 of 2 | +9.5% |
| Feb | 3 | 1 of 3 | −5.1% |
| Mar | 3 | 1 of 3 | −13% |
| Apr | 3 | 2 of 3 | +14% |
| May | 3 | 1 of 3 | +4.9% |
| Jun | 3 | 2 of 3 | +3.3% |
| Jul | 3 | 1 of 3 | −1.2% |
| Aug | 3 | 2 of 3 | +6.7% |
| Sep | 3 | 1 of 3 | −4.9% |
| Oct | 3 | 2 of 3 | −6.1% |
| Nov | 2 | 2 of 2 | +12% |
| Dec | 2 | 0 of 2 | −12% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry